首頁 > 市場調查報告書 > 製藥

3D列印

市場調查報告書

商品編碼

1554287

3D 列印藥品市場規模、佔有率和成長分析：按劑型、技術類型、應用和地區 - 產業預測，2024-2031 年

3D Printed Drugs Market Size, Share, Growth Analysis, By Dosage Form (Tablet, Capsule), By Technology Type (Inkjet Printing, Direct Write), By Application (Orthopedic, Neurology), By Region - Industry Forecast 2024-2031

出版日期: 2024年09月01日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球3D列印藥品市場規模為8,490萬美元，從2023年的9,850萬美元成長到2031年的3.2291億美元，預計在預測期內（2024-2031年）複合年成長率為16%。

全球3D列印藥品市場在製藥領域正經歷快速成長。這項技術擴大被用來生產定製藥物配方、提高藥物療效、最大限度地減少副作用並實現個人化劑量。藥品製造中的 3D 列印在基材上逐層列印精確劑量的藥物，提供更個人化的治療方法。北美市場領先，其次是歐洲和亞太地區。推動這一成長的關鍵因素包括對個人化醫療的需求不斷成長、3D 列印提供的精確性和減少的副作用以及持續的技術進步。 3D 列印製藥市場的主要目標是引入創新的藥物製造方法，以改善患者的治療效果並降低醫療成本。 3D列印技術使藥物設計更加靈活，最大限度地減少浪費，並促進按需生產。儘管有這些優勢，3D列印技術仍面臨高成本和藥物核准監管障礙等挑戰。其他挑戰包括需要進一步研究以確保安全性和有效性、印刷過程的標準化以及潛在的智慧財產權衝突。然而，市場上也存在重大機遇，包括新配方的開發、新地區的擴張以及藥物輸送和個人化醫療轉型的潛力。該技術還有可能為製藥公司創造新的收益來源。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Aprecia Pharmaceuticals, LLC（US）
FabRx Ltd（UK）
Cycle Pharmaceuticals（UK）
GlaxoSmithKline plc（UK）
AstraZeneca（UK/Sweden）
Tvasta（India）
Merck KGaA（Germany）
Terumo Corporation（Japan）
Extend Biosciences（US）
BioDuro（US）
Affinity Therapeutics（US）
Osmotica Pharmaceuticals（US）
Pfizer（US）
Sanofi（France）
3D Systems（US）
BASF（Germany）
Teva Pharmaceuticals（Israel）
Novartis（Switzerland）
Roche（Switzerland）
Catalent（US）
Johnson & Johnson（US）
Vertex Pharmaceuticals（US）
Boehringer Ingelheim（Germany）
Siemens Healthineers（Germany）
Sandoz International（Germany）
BioBots（US）
Apium Additive Technologies（Germany）
Boston Micro Fabrication（US）

簡介目錄

Product Code: SQMIG35I2140

Global 3D Printed Drugs Market size was valued at USD 84.9 Million in 2022 and is poised to grow from USD 98.50 Million in 2023 to USD 322.91 Million by 2031, at a CAGR of 16% during the forecast period (2024-2031).

The global market for 3D-printed drugs is experiencing rapid growth within the pharmaceutical sector. This technology is increasingly utilized to produce customized drug formulations, enhancing drug effectiveness, minimizing side effects, and enabling personalized dosing. 3D printing in drug manufacturing involves the layer-by-layer creation of precise doses of medication on a substrate, offering a more tailored approach to treatment. North America leads the market, followed by Europe and Asia Pacific. Key factors driving this growth include the rising demand for personalized medicine, the precision and reduced side effects afforded by 3D printing, and ongoing technological advancements. The main objectives of the 3D-printed drugs market are to introduce innovative drug manufacturing methods that enhance patient outcomes and lower healthcare costs. 3D printing technology enables more flexible drug design, minimizes waste, and facilitates on-demand production. Despite these advantages, the market faces challenges such as high costs associated with 3D printing technology and regulatory hurdles for drug approval. Additional challenges include the need for further research to ensure safety and efficacy, standardization of printing processes, and potential intellectual property conflicts. However, the market also holds significant opportunities, such as the development of novel drug formulations, expansion into new regions, and the potential transformation of drug delivery and personalized medicine. This technology could also open new revenue streams for pharmaceutical companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global 3D Printed Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global 3D Printed Drugs Market Segmental Analysis

The global 3D printed drugs market is segmented based on dosage form, technology, application, and region. Based on technology, the market is segmented into Inkjet Printing, Direct Write, Zip Dose, Thermal Inkjet Printing, Fused Deposition Modelling, Powder Bed Printing, Stereolithography (SLA) and Semi Solid Extrusion (SSE). Based on application, the market is segmented into orthopedics, neurology, dental, and others. Based on dosage form, the market is segmented into Tablet, Capsule, Multidrug Implant, Nanoparticles, Solutions and Other Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and MEA.

Drivers of the Global 3D Printed Drugs Market

The global market for 3D-printed drugs is being significantly driven by the growing demand for personalized medicines. These medicines, tailored to individual patients based on their genetic, environmental, and lifestyle factors, offer numerous benefits over conventional drugs, such as enhanced efficacy, fewer side effects, and better patient adherence. 3D printing technology plays a crucial role in this sector by enabling the production of customized drug formulations with precise dosing and specific drug release profiles. This technology allows for the creation of drug products with unique geometries and formulations that traditional manufacturing methods cannot achieve. The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, further fuels the demand for personalized medicines. Such conditions often require ongoing treatment, and personalized drugs can significantly improve patient outcomes and overall quality of life. By facilitating targeted drug delivery, 3D printing can reduce the necessary dosage, thereby minimizing side effects and enhancing patient compliance. As both the demand for personalized medications and advancements in 3D printing technology continue to grow, the global 3D-printed drugs market is anticipated to expand rapidly in the coming years.

Restraints in the Global 3D Printed Drugs Market

he substantial initial investment needed for 3D printing equipment, software, and materials poses a significant challenge for small and medium-sized pharmaceutical companies looking to adopt this technology. The high costs associated with these resources can make 3D printing less accessible for many companies, limiting their ability to participate in the market. Additionally, the cost per unit for 3D-printed drugs tends to be higher compared to traditional drugs, primarily due to the expensive materials and the intricate production process involved. This higher cost can make 3D-printed medications less affordable for patients, potentially diminishing their market demand. Moreover, the regulatory landscape for 3D-printed drugs is still evolving, with approval processes often being both lengthy and costly. This regulatory uncertainty can further drive up the costs associated with 3D-printed drugs and restrict their availability to patients. As a result, the combination of high production costs and regulatory challenges can limit the widespread adoption and accessibility of 3D-printed pharmaceuticals.

Market Trends of the Global 3D Printed Drugs Market

The increasing collaboration between pharmaceutical companies and 3D printing firms is significantly advancing the global 3D Printed Drugs market. This partnership is accelerating innovation and expediting the development and market entry of new drugs and drug delivery systems. By working together, pharmaceutical companies and 3D printing specialists are leveraging the technology's capabilities to create complex and customized drug formulations with precise dosing and tailored characteristics. These collaborations are not only streamlining the development process but are also contributing to faster market introductions of novel drug products and delivery mechanisms. As this trend continues, it is expected to drive further growth in the 3D printed drugs sector, enhancing the industry's ability to meet evolving medical needs and patient preferences in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Value Chain Analysis
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Pricing analysis
Value chain analysis
Patent analysis
Regulatory analysis
Porter's five forces analysis

Global 3D Printed Drugs Market by Dosage Form

Market Overview
Tablet
Capsule
Multidrug Implant
Nanoparticles
Solutions
Other Products

Global 3D Printed Drugs Market by Technology Type

Market Overview
Inkjet Printing
Direct Write
Zip Dose
Thermal Inkjet Printing
Fused Deposition Modelling
Powder Bed Printing
Stereolithography (SLA)
Semi Solid Extrusion (SSE)

Global 3D Printed Drugs Market by Application

Market Overview
Orthopedic
Neurology
Dental
Others

Global 3D Printed Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Aprecia Pharmaceuticals, LLC (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
FabRx Ltd (UK)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Cycle Pharmaceuticals (UK)
- Company overview
- Business segment overview
- Financial updates
- Key developments
GlaxoSmithKline plc (UK)
- Company overview
- Business segment overview
- Financial updates
- Key developments
AstraZeneca (UK/Sweden)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Tvasta (India)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Merck KGaA (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Terumo Corporation (Japan)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Extend Biosciences (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
BioDuro (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Affinity Therapeutics (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Osmotica Pharmaceuticals (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Pfizer (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Sanofi (France)
- Company overview
- Business segment overview
- Financial updates
- Key developments
3D Systems (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
BASF (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Teva Pharmaceuticals (Israel)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Novartis (Switzerland)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Roche (Switzerland)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Catalent (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Johnson & Johnson (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Vertex Pharmaceuticals (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Boehringer Ingelheim (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Siemens Healthineers (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Sandoz International (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
BioBots (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Apium Additive Technologies (Germany)
- Company overview
- Business segment overview
- Financial updates
- Key developments
Boston Micro Fabrication (US)
- Company overview
- Business segment overview
- Financial updates
- Key developments